secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001737287-23-000067
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports updated Phase 1 data for ALLO-501/501A in r/r LBCL with 58% ORR and 42% CR
--------------------------------------------------------------------------------

- In 33 CAR T-naïve patients, ORR 58%, CR 42%; 30% maintained CR at 6 months across all patients.
- Phase 2 regimen (12 patients): ORR 67%, CR 58%; median duration of response 23.1 months.
- No Grade ≥3 CRS, no ICANS or GvHD; cytopenia and infections manageable, comparable to autologous CAR T.
- Company expects to complete enrollment of potentially pivotal Phase 2 ALPHA2 trial in 1H2024; plans to open sites in Europe, Canada, Australia in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000067/0001737287-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000067/allo-20230615.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer